Topical bismuth oxide-manganese composite nanospheres alleviate atopic dermatitis-like inflammation

• Published in: Journal of nanobiotechnology 2023-11, Vol.21 (1), p.430
• Main Authors: Li, Mengjie, Chen, Benjin, Xu, Lingling, Wang, Yu, Chen, Zhu, Ma, Bingyan, Qin, Shichun, Jiang, Yechun, Gu, Cheng, Qian, Haisheng, Xiao, Fengli
• Format: Article
• Language: English
• Subjects: Advertising executives; Analysis; Animal models; Animals; Atopic dermatitis; Bismuth; Bismuth oxides; Care and treatment; Cell culture; Cell differentiation; Chemokines; Cytokines; Cytokines - metabolism; Dermatitis; Dermatitis, Atopic - drug therapy; Dermatitis, Atopic - pathology; Dermatologic agents; Dermatology; Drug therapy; Eczema; Electrons; Filaggrin; Formulae, receipts, prescriptions; GATA-3 protein; Health aspects; Helper cells; Hydrogels; Inflammation; Inflammation - pathology; Interleukin 4; Interleukin-4 - metabolism; Interleukin-4 - pharmacology; Interleukin-4 - therapeutic use; Kinases; Lymphocytes T; Manganese; Manganese - pharmacology; Mice; Mice, Inbred C57BL; Nanoparticles; Nanospheres; Phenotypes; Phosphorylation; Proteins; Rheology; Skin; Skin diseases; Skin lesions; Stat6 protein; Testing; Transmission electron microscopy
• ISSN: 1477-3155; 1477-3155
• DOI: 10.1186/s12951-023-02207-4

Atopic dermatitis (AD) is a common skin disease involving important immune mechanisms. There is an unmet need for a treatment for this condition. Herein, we focused on elucidating the role of Bi Mn O nanospheres (BM) in alleviating skin inflammation in AD-like C57BL/6 mice. The BM was fabricated via sacrificial templates and its biosafety was systematically evaluated. The BM was applied topically to skin lesions of AD-like C57BL/6 mice. The phenotypic and histological changes in the skin were examined carefully. The responses of barrier proteins, inflammatory cytokines and cells to BM were evaluated in HaCaT cells and AD mouse models. The data demonstrated that BM treatment alleviated the AD phenotypes and decreased the level of inflammatory factors, while increasing the expression of the barrier proteins filaggrin/involucrin in the skin. BM effectively reduced the expression of phosphorylated STAT6, which in turn reduced the expression of GATA3, and further decreased the differentiation ratio of Th2 cells, thereby reducing the expression of IL-4. In conclusion, topical drug therapy with BM provides a safe and effective treatment modality for AD by reducing IL-4 and increasing barrier proteins.